FibroGen (FGEN) Appoints Michael Kauffman to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/11/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
- AppLovin gains market share among e-commerce advertisers
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors
June 9, 2025 4:02 PM EDTSAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025.
Michael is a well-recognized biotech industry veteran, who brings a wealth of biotech leadership experience to our board, said James Schoeneck, chairman of the board of directors of FibroGen. His expertise spanning all stages of drug development will be invaluable as FibroGen progresses its pipeline. Michaels deep understanding of oncology will help the company through anticipated near-term clinical milestones and potential value-drivers.
FibroGen has differentiated potential... More
